| Literature DB >> 36118670 |
Yu Pan1, Xiaoyang Miao2, Ou Jin1, Jingye Pan2, Yihua Dong2.
Abstract
Background: Alcohol use disorder (AUD) is common in critically ill patients. Plasma anion gap (AG) was known as a feasible parameter and was associated with outcomes of various diseases. This study is intended to explore whether AG is related to 28-day inhospital mortality and 1-year mortality of critically ill patients with AUD. Method: We extracted data from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. The association of plasma AG with 28-day inhospital mortality and 1-year mortality of critically ill AUD patients was assessed using Cox proportional hazard regression models and stratification analyses, allowing AG as a time-varying covariate in the models. To evaluate the accuracy of AG in predicting different endpoints, receiver operator characteristic (ROC) curves were used. Result: Among the 3993 critically ill patients with AUD, AG was positively associated with 28-day inhospital mortality and 1-year mortality after adjusting confounders (p < 0.001 for all). Compared with lower AG (<12 mmol/L), patients in different groups (12 ≤ AG < 14 mmol/L, 14 ≤ AG < 17 mmol/L, 17 ≤ AG < 20 mmol/L, and AG ≥ 20 mmol/L) had different HRs (95% CIs) for 28-day inhospital mortality (1.105, (0.906, 1.347); 1.171, (0.981, 1.398); 1.320, (1.108, 1.573); and 1.487, (1.254, 1.763), respectively) and 1-year mortality (1.037 (0.898, 1.196); 1.091 (0.955, 1.246); 1.201 (1.052, 1.371); and 1.3093 (1.149, 1.492), respectively).Entities:
Mesh:
Year: 2022 PMID: 36118670 PMCID: PMC9473916 DOI: 10.1155/2022/5039964
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.464
Figure 1Study chart.
Baseline characteristics between AG groups.
| Variable | AG (mmol/L) | |||||
|---|---|---|---|---|---|---|
| AG < 12 | 12 ≤ AG < 14 | 14 ≤ AG < 17 | 17 ≤ AG < 20 | AG ≥ 20 |
| |
| ( | ( | ( | ( | ( | ||
| Age (years) | 58.00 (48.00-66.00) | 56.00 (47.00-65.00) | 55.00 (45.00-64.00) | 54.00 (44.00-64.00) | 54.00 (45.00-62.00) | <0.001 |
| Sex (male), | 209 (73.85%) | 388 (76.98%) | 788 (73.03%) | 683 (71.00%) | 852 (73.13%) | 0.191 |
| Time in ICU (days) | 2.29 (1.49-4.72) | 2.53 (1.57-5.16) | 2,63 (1.58-5.34) | 2.73 (1.71-6.01) | 2.79 (1.70-6.04) | 0.002 |
| Time in hospital (days) | 7.96 (5.08-12.83) | 7.73 (4.59-14.26) | 8.29 (4.71-14.96) | 8.23 (4.58-15.54) | 8.42 (4.17-15.58) | 0.803 |
| 28-day inhospital mortality, | 13 (4.59%) | 31 (6.15%) | 82 (7.60%) | 105 (10.91%) | 218 (18.71%) | <0.001 |
| 1-year mortality, | 19 (6.71%) | 45 (8.93%) | 108 (10.01%) | 137 (14.24%) | 243 (20.86%) | <0.001 |
| Vital signs | ||||||
| Anion gap | 10.00 (10.00-11.00) | 13.00 (12.00-13.00) | 15.00 (14.00-16.00) | 18.00 (17.00-19.00) | 23.00 (21.00-27.00) | <0.001 |
| Scoring systems | ||||||
| SOFA | 5.00 (3.00-7.00) | 4.00 (2.00-7.00) | 4.00 (2.00-7.00) | 5.00 (3.00-8.00) | 7.00 (3.00-11.00) | <0.001 |
| LODS | 4.00 (2.00-6.00) | 3.00 (2.00-6.00) | 4.00 (2.00-6.00) | 4.00 (2.00-7.00) | 5.00 (3.00-9.00) | <0.001 |
| SAPSII | 29.00 (22.00-36.00) | 28.00 (21.00-37.00) | 29.00 (21.00-37.00) | 31.00 (22.00-41.00) | 35.00 (25.00-48.00) | <0.001 |
| QSOFA, | 0.001 | |||||
| 0 | 6 (2.12%) | 13 (2.58%) | 27 (2.50%) | 27 (2.81%) | 23 (1.97%) | |
| 1 | 67 (23.67%) | 121 (24.01%) | 251 (23.26%) | 196 (20.37%) | 268 (23.00%) | |
| 2 | 144 (50.88%) | 241 (47.82%) | 489 (45.32%) | 468 (48.65%) | 468 (40.17%) | |
| 3 | 66 (23.32%) | 129 (25.60%) | 312 (28.92%) | 271 (28.17%) | 406 (34.85%) | |
| SIRS, | <0.001 | |||||
| 0 | 7 (2.47%) | 11 (2.18%) | 14 (1.30%) | 6 (0.62%) | 6 (0.52%) | |
| 1 | 42 (14.84%) | 53 (10.52%) | 100 (9.27%) | 79 (8.21%) | 63 (5.41%) | |
| 2 | 90 (31.80%) | 179 (35.52%) | 351 (32.53%) | 335 (34.82%) | 332 (28.50%) | |
| 3 | 103 (36.40%) | 192 (38.10%) | 431 (39.94%) | 359 (37.32%) | 332 (28.50%) | |
| 4 | 41 (14.49%) | 69 (13.69%) | 183 (16.96%) | 183 (19.02%) | 262 (22.49%) | |
| Ethnicity, | <0.001 | |||||
| White | 195 (68.90%) | 318 (63.10%) | 669 (62.00%) | 612 (63.62%) | 700 (60.09%) | |
| Black | 12 (4.24%) | 25 (4.96%) | 94 (8.71%) | 87 (9.04%) | 141 (12.10%) | |
| Hispanic | 7 (2.47%) | 26 (5.16%) | 45 (4.17%) | 39 (4.05%) | 50 (4.29%) | |
| Others | 69 (24.38%) | 135 (26.79%) | 271 (25.12%) | 224 (23.28%) | 274 (23.52%) | |
| First care unit, | <0.001 | |||||
| MICU | 87 (30.74%) | 146 (28.97%) | 322 (29.84%) | 318 (33.06%) | 481 (41.29%) | |
| CCU | 62 (21.91%) | 87 (17.26%) | 218 (20.20%) | 181 (18.81%) | 172 (14.76%) | |
| SICU | 33 (11.66%) | 82 (16.27%) | 173 (16.03%) | 150 (15.59%) | 166 (14.25%) | |
| MICU/SICU | 14 (4.95%) | 36 (7.14%) | 68 (6.30%) | 72 (7.48%) | 87 (7.47%) | |
| CVICU | 31 (10.95%) | 70 (13.89%) | 171 (15.85%) | 158 (16.42%) | 188 (16.14%) | |
| TSICU | 54 (19.08%) | 57 (11.31%) | 78 (7.23%) | 28 (2.91%) | 25 (2.15%) | |
| Others | 2 (0.71%) | 26 (5.16%) | 49 (4.54%) | 55 (5.72%) | 46 (3.95%) | |
| Ventilation, | 237 (83.75%) | 421 (83.53%) | 863 (79.98%) | 732 (76.09%) | 912 (78.28%) | 0.003 |
| Vasopression, | 8 (2.83%) | 19 (3.77) | 57 (5.28%) | 76 (7.90%) | 167 (14.33%) | <0.001 |
| Major comorbidities, | ||||||
| Sepsis | 156 (55.12%) | 292 (57.94%) | 575 (53.29%) | 523 (54.37%) | 731 (62.75%) | <0.001 |
| Myocardial infarct | 30 (10.60%) | 43 (8.53%) | 95 (8.80%) | 84 (8.73%) | 107 (9.18%) | 0.877 |
| Congestive heart failure | 33 (11.66%) | 73 (14.48%) | 184 (17.05%) | 148 (15.38%) | 173 (14.85%) | 0.207 |
| Peripheral vascular disease | 28 (9.89%) | 33 (6.55%) | 77 (7.14%) | 66 (6.86%) | 56 (4.81%) | 0.019 |
| Cerebrovascular disease | 19 (6.71%) | 55 (10.91%) | 135 (12.51%) | 128 (13.31%) | 93 (7.98%) | <0.001 |
| Peptic ulcer disease | 16 (5.65%) | 24 (4.76%) | 48 (4.45%) | 34 (3.53%) | 57 (4.89%) | 0.481 |
| Mild liver disease | 122 (43.11%) | 202 (40.08%) | 362 (33.55%) | 353 (36.69%) | 581 (49.87%) | <0.001 |
| Severe liver disease | 76 (26.86%) | 114 (22.62%) | 194 (17.98%) | 181 (18.81%) | 315 (27.04%) | <0.001 |
| Chronic pulmonary disease | 64 (22.61%) | 128 (25.40%) | 246 (22.80%) | 200 (20.79%) | 205 (17.60%) | 0.002 |
| Renal disease | 11 (3.89%) | 27 (5.36%) | 65 (6.02%) | 100 (10.40%) | 150 (12.88%) | <0.001 |
| Metastatic solid tumor | 9 (3.18%) | 12 (2.38%) | 36 (3.34%) | 21 (2.18%) | 26 (2.23%) | 0.398 |
| Malignant cancer | 29 (10.25%) | 41 (8.13%) | 91 (8.43%) | 60 (6.24%) | 74 (6.35%) | 0.056 |
| Aids | 2 (0.71%) | 3 (0.60%) | 10 (0.93%) | 9 (0.94%) | 9 (0.77%) | 0.952 |
Abbreviations: AG: anion gap; CCU: cardiac care unit; CVICU: cardiovascular intensive care unit; ICU: intensive care unit; LODS: logistic organ dysfunction system; MICU: medical intensive care unit; QSOFA: quick sepsis-related organ failure assessment; SAPSII: simplified acute physiology score II; SICU: surgical intensive care unit; SIRS: systemic inflammatory response syndrome; SOFA: sequential organ failure assessment; TSICU: trauma and surgical intensive care unit.
Figure 2ROC curve for 28-day inhospital mortality.
Time-varying HRs and 95% CI for AG in association with 28-day inhospital mortality from Cox models.
| Nonadjusted | Adjusted I | Adjusted II | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| |
| AG | 1.022 (1.018, 1.026) | <0.0001 | 1.023 (1.020, 1.027) | <0.0001 | 1.013 (1.010, 1.017) | <0.0001 |
| AGQuintile | ||||||
| AG < 12 | 1 | 1 | 1 | |||
| 12 ≤ AG < 14 | 1.092 (0.901, 1.324) | 0.3700 | 1.100 (0.906, 1.335) | 0.3348 | 1.105 (0.906, 1.347) | 0.3265 |
| 14 ≤ AG < 17 | 1.167 (0.981, 1.387) | 0.0818 | 1.189 (0.999, 1.415) | 0.0509 | 1.171 (0.981, 1.398) | 0.0805 |
| 17 ≤ AG < 20 | 1.305 (1.099, 1.550) | 0.0024 | 1.321 (1.112, 1.568) | 0.00153 | 1.320 (1.108, 1.573) | 0.00191 |
| AG ≥ 20 | 1.563 (1.320, 1.851) | <0.0001 | 1.596 (1.347, 1.891) | <0.0001 | 1.487 (1.254, 1.763) | <0.0001 |
| AG | 1.134 (1.104, 1.165) | <0.0001 | 1.141 (1.111, 1.172) | <0.0001 | 1.102 (1.073, 1.131) | <0.0001 |
Abbreviations: AG: anion gap; CI: confidence interval; HR: hazard ratio. Adjusted I for age, gender, and ethnicity. Adjusted II for age, ethnicity, time in hospital, ventilation, vasopression, sepsis, cerebrovascular disease, mild liver disease, peptic ulcer disease, severe liver disease, and metastatic solid tumor. Reference group: AG < 12 mmol/L.
Time-varying HRs and 95% CI for AG in association with 1-year mortality from Cox models.
| Nonadjusted | Adjusted I | Adjusted II | ||||
|---|---|---|---|---|---|---|
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| |
| AG | 1.016 (1.013, 1.019) | <0.0001 | 1.018 (1.015, 1.021) | <0.0001 | 1.010 (1.007, 1.013) | <0.0001 |
| AGQuintile | ||||||
| AG < 12 | 1 | 1 | 1 | |||
| 12 ≤ AG < 14 | 1.073 (0.933, 1.234) | 0.3230 | 1.083 (0.941, 1.247) | 0.2657 | 1.037 (0.898, 1.196) | 0.62276 |
| 14 ≤ AG < 17 | 1.103 (0.969, 1.256) | 0.1370 | 1.129 (0.992, 1.286) | 0.06705 | 1.091 (0.955, 1.246) | 0.20161 |
| 17 ≤ AG < 20 | 1.221 (1.074, 1.388) | 0.0022 | 1.243 (1.093, 1.413) | 0.000915 | 1.201 (1.052, 1.371) | 0.006585 |
| AG ≥ 20 | 1.378 (1.210, 1.569) | <0.0001 | 1.409 (1.237, 1.605) | <0.0001 | 1.309 (1.149, 1.492) | <0.0001 |
| AG | 1.090 (1.067, 1.114) | <0.0001 | 1.097 (1.073, 1.120) | <0.0001 | 1.067 (1.045, 1.090) | <0.0001 |
Abbreviations: AG: anion gap; CI: confidence interval; HR: hazard ratio. Adjusted I for age, gender, and ethnicity. Adjusted II for age, ethnicity, gender, time in hospital, ventilation, vasopression, sepsis, cerebrovascular disease, peptic ulcer disease, mild liver disease, renal disease, severe liver disease, and metastatic solid tumor. Reference group: AG < 12 mmol/L.
Figure 3Kaplan-Meier curve of 28-day inhospital mortality for overall survival analysis of different AG categories.
Figure 4Kaplan-Meier curve of 1-year mortality for overall survival analysis of different AG categories.
Figure 5Subgroup analysis of the association between different AG categories and 28-day inhospital mortality.